From foresight to investability: what Europe’s 25 technology signals tell investors
The European Innovation Council consistently tries to name technologies that may become important before the rest of the market has fully formed around them. Its latest effort is the Tech Report 2026, listing 25 such technologies, including everything from AI agents that learn to handle messy, real-world environments to robots that service satellites and MRI machines light enough to wheel to a hospital bed.
The EIC describes each technology on its list as a signal. They represent early signs of what “might” become important. For investors, the useful question is how far each signal has moved towards something they can actually underwrite.
To find that line, Zubr Capital analysts examined each of the 25 technologies for evidence of European company formation and private investment. They then reviewed Q2 2026 financing activity, private rounds, debt, grants and other public funding — to see where isolated private bets may be turning into a repeated funding pattern.
Finding Patterns in Private Bets
The clearest outlier in the list was embodied AI. Five independent private rounds in Q2 2026 backed European companies working around the same broad technological shift. No other EIC signal had that same concentration of fresh bets from private investors. Embodied AI is the clearest case of an EIC signal moving beyond isolated company-level bets and into an emerging investable category.
The next question is why this signal moved further than the others. Some of the answer is in the market it’s entering. Manufacturers and logistics companies already spend heavily on automation. They already know where conventional systems fall short. Traditional robots work extremely well when parameters and environments are predictable. Those same tools are harder to justify when work is more variable. Embodied AI is trying to extend such automation into those more complex areas.
THEKER demonstrates why that matters commercially. Based in Barcelona, the company has tested its technology inside Inditex’s operations. Inditex then invested. The customer and the investor are the same company. Such an investment is evidence of an industrial buyer recognizing a problem worth solving and a technology worth testing against it.
THEKER is not the only example of such activity. The five Q2 rounds appeared across the funding ladder. All3 raised $25 million in seed funding. THEKER raised €73 million at Series A, Smart Robotics €10 million at Series A, Sereact €93 million at Series B, and NEURA Robotics closed a Series C of up to €1.2 billion. The fresh capital appearing across multiple companies and development stages is more important than the total amount.
NEURA’s products and route to market differ from THEKER’s. However, the underlying commercial logic is much the same: make robots capable of handling more of the work companies already want to automate. The scale of financing in this Q2 cluster highlights that it extends beyond early experimentation into companies pursuing larger industrial deployments.
Examples like these explain why embodied AI stands out in the EIC’s list. The commercial challenge is not necessarily to create a new spending category from scratch. It is to show that a new generation of robots can handle more varied work that companies already spend money trying to automate. In Q2 2026, investors were making that bet at several points along the company-building curve.
How a Technology Signal Becomes a Private Bet
While embodied AI stands out for Q2 activity with private bets repeating across multiple European companies, private capital has already reached much of the EIC list. For another 16 signals, we found a European company built around the technology and at least one private investment.
In Q2 2026, four of those signals had attracted fresh private capital. Ubotica raised $11 million for satellite edge computing. Mbiomics added €12 million to develop a microbiome therapy for cancer patients. Imperagen raised £5 million for computational protein design. SonoMind raised €20 million for a focused ultrasound treatment for depression.
The companies in these rounds are quite different. One already has technology operating in space; another is developing a drug; a third works with industrial customers; the fourth still has a medical treatment to prove. They are not at the same stage of commercial development. That means there is no single maturity threshold at which private capital appears. The next thing to look at is what, exactly, each company has built around the technology.
Ubotica, for example, focuses more on the hardware and software that can fly on satellites and the services built on the data they process. Mbiomics has a named drug candidate, MBX-116, as well as a clinical program that targets defined milestones. Imperagen has narrowed the focus of computational protein design into making enzymes more effective for industrial processes. SonoMind is doing the same, but in an entirely different field, turning brain interface research into a specific treatment that can be tested, approved and eventually sold.
What all four companies demonstrate is that the broad technology signal has already become a specific company proposition. From there, the next use of capital becomes easier to define.
For private investors, that is where an emerging technology starts becoming actionable. The science may still be risky and the market years away, but a defined product or asset and a recognizable route to customers or end markets make the opportunity more legible to investors. That also helps clarify what the next funding round is meant to achieve. At that point, the investor is no longer being asked to finance a possibility. There is finally a company to invest in.
Before there is a company
That leaves eight EIC signals for which we could not find any qualifying private investment. Microbial biomining is at the threshold. There is a European company already built around the technology, but we could not verify a private bet. For the other seven, the gap appears earlier. We could identify the general direction of the technology, but not a European company built around it.
Spin caloritronics is an example. It could eventually convert low-grade waste heat into electricity or useful signals, but efficiency remains modest. Even integrating such technology into a working module remains an early-stage challenge. Biohybrid microrobots have an equally clear destination. Tiny systems combining living and synthetic components may navigate the body to deliver drugs and other therapies, but the field is only now moving towards preclinical use. With passive cooling and gravity-based energy storage, the EIC list points to new ways for buildings to manage heat and power, before an obvious business has formed around that exact combination.
In these cases, the missing piece is not the use case. It is the product and the company that could turn it into a business. What exactly gets sold? Who buys it? What technical achievement makes it commercially valuable? And what would the first serious round of private capital actually be paying to prove?
The privately backed companies above could already answer those questions, however early they still were. Uncertainty sits where investors aren’t choosing whether to back a particular company. It’s where the market is still trying to understand what that company could be.
Here is where the difference between foresight and investing becomes clearest. The EIC can flag a technological route because the science suggests it may matter one day. Private capital requires something more concrete before acting on the same idea.
One question, not twenty-five. The Zubr Capital investor lens
In March, embodied AI and biohybrid microrobots sat side by side on the EIC’s list. They were two early signals that still sounded more like the future than established industries. By June, they looked very different from an investor’s perspective. Embodied AI had drawn five independent private rounds backing European companies in Q2 alone. Biohybrid microrobots, by contrast, had drawn none. The medical promise is easy enough to understand, but for now, the company a growth investor would actually be funding is much harder to point to.
That difference does not show up if you only ask whether the science is real, whether the potential market is huge, or whether the technology is making progress. Biohybrid microrobots are moving towards application-relevant systems and preclinical testing. Several of the other EIC signals without a private cheque are advancing too. The question is more about what is being sold, to whom, and what the next cheque is meant to prove. With embodied AI, the answer is in Barcelona, where THEKER’s technology is already running within the operations of a customer that then became an investor. Biohybrid microrobots can describe the end goal but cannot yet answer those other practical questions nearly as cleanly.
These questions are not unique to deep tech. They are questions a growth investor asks at every later round. Together, they come down to a single question: what does this money buy that we do not have today? What changes at the frontier is when that question has to be asked — not once a company exists with a term sheet on the table, but earlier, while the same idea is still wearing the label “signal” in a foresight report.
Our classification is still a snapshot, not a forecast. Some signals may spend years waiting for someone to turn promising science into a viable product and company. That is precisely what makes the EIC’s 25 signals useful. Even before all 25 are investable, the report can show investors where a technology may be going; the business taking shape around it shows when it becomes an investable proposition.
For more startup news, check out the other articles on the website, and subscribe to the magazine for free. Listen to The Cereal Entrepreneur podcast for more interviews with entrepreneurs and big-hitters in the startup ecosystem.
